Screening and Identification of Key Genes for Clinical Benefit of Immunotherapy on Lung Adenocarcinoma Based on TCGA Database

QI Xiaoguang; QI Chunyan; QIN Boyu; HU Yi; HAN Weidong

doi:10.3971/j.issn.1000-8578.2020.20.0115

Cancer Research on Prevention and Treatment > 2020 > 47(11): 839-845. > DOI: 10.3971/j.issn.1000-8578.2020.20.0115

QI Xiaoguang, QI Chunyan, QIN Boyu, HU Yi, HAN Weidong. Screening and Identification of Key Genes for Clinical Benefit of Immunotherapy on Lung Adenocarcinoma Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 839-845. DOI: 10.3971/j.issn.1000-8578.2020.20.0115

Citation:

PDF (7393 KB)

Screening and Identification of Key Genes for Clinical Benefit of Immunotherapy on Lung Adenocarcinoma Based on TCGA Database

1.
Department of Oncology, Chinese PLA General Hospital, Beijing 100853, China
2.
Department of Special Ward, Chinese PLA General Hospital, Beijing 100853, China
3.
Department of Biotherapy, Chinese PLA General Hospital, Beijing 100853, China

More Information

Corresponding author:
HU Yi, E-mail: huyi0401@aliyun.com
Received Date: February 18, 2020
Revised Date: September 09, 2020
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To identify key biomarkers for predicting the response to immunotherapy and elucidate the possible underlying mechanism in lung adenocarcinoma based on whole-genome sequencing.
Methods
Data set of MSKCC (Science 2015) with lung adenocarcinoma from TCGA database were downloaded. According to the duration time of response to immunotherapy, two groups were divided: durable clinical benefit (DCB) group and non-durable clinical benefit (Non-DCB) group. The differences in gene mutation spectrum between the two groups were analyzed. The key genes and underlying biological functions of immunotherapy for lung adenocarcinoma were further analyzed.
Results
There were differences in gene mutation spectrum between the DCB group and the Non-DCB group. In the DCB group, these key genes were mainly involved in Ca signaling pathway, Rap1 and PI3K-AKT pathways. The top 6 hub genes (KRAS, PPP2CB, CDC20, DYNC1I2, BRCA1 and AKAP9) were screened using the PPI network analysis. CDC20 and BRCA1 were associated with the prognosis of lung adenocarcinoma patients.
Conclusion
The hub genes involved in the DCB group might be important to guide the classification of immune signature and improve precision immunotherapy for lung adenocarcinoma. In addition, CDC20 and BRCA1 might be potential therapeutic targets for immunotherapy of lung adenocarcinoma.
- Lung cancer,
- Immunotherapy,
- Biomarkers,
- TCGA,
- Bioinformatics analysis

FullText(HTML)

References (22)

References

[1]	Suresh K, Naidoo J, Lin CT, et al. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities[J]. Chest, 2018, 154(6): 1416-1423. doi: 10.1016/j.chest.2018.08.1048
[2]	Haanen JB, Robert C. Immune Checkpoint Inhibitors[J]. Prog Tumor Res, 2015, 42: 55-66. http://esmoopen.bmj.com/lookup/external-ref?access_num=25823918&link_type=MED&atom=%2Fesmoopen%2F2%2F4%2Fe000247.atom
[3]	Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2018, 97(33): e11936. doi: 10.1097/MD.0000000000011936
[4]	Janakiram M, Pareek V, Cheng H, et al. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies[J]. Immunotherapy, 2016, 8(7): 809-819. doi: 10.2217/imt-2016-0001
[5]	Lantuejoul S, Damotte D, Hofman V, et al. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma[J]. J Thorac Dis, 2019, 11(Suppl 1):S89-S101.
[6]	Jang HJ, Lee HS, Ramos D, et al. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors[J]. J Thorac Cardiovasc Surg, 2019, 159(4): 1589-1610. http://www.researchgate.net/publication/337174405_Transcriptome-based_Molecular_Subtyping_of_Non-Small_Cell_Lung_Cancer_may_Predict_Response_to_Immune_Checkpoint_Inhibitors
[7]	Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing[J]. J Clin Oncol, 2018, 36(7): 633-641.. doi: 10.1200/JCO.2017.75.3384
[8]	Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab[J]. Nat Med, 2018, 24(9):1441-1448. doi: 10.1038/s41591-018-0134-3
[9]	Wang S, Chen B, Zhu Z, et al. CDC20 overexpression leads to poor prognosis in solid tumors: A system review and meta-analysis[J]. Medicine (Baltimore), 2018, 97(52): e13832. doi: 10.1097/MD.0000000000013832
[10]	Alfarsi LH, Ansari RE, Craze ML, et al. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy[J]. Breast Cancer Res Treat, 2019, 178(3): 535-544. doi: 10.1007/s10549-019-05420-8
[11]	Zhang Q, Huang H, Liu A, et al. Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells[J]. EBio Medicine, 2019, 42: 397-407. http://www.ncbi.nlm.nih.gov/pubmed/30904606
[12]	Cheng S, Castillo V, Sliva D, et al. CDC20 associated with cancer metastasis and novel mushroom-derived CDC20 inhibitors with antimetastatic activity[J]. Int J Oncol, 2019, 54(6): 2250-2256. http://www.researchgate.net/publication/332512404_CDC20_associated_with_cancer_metastasis_and_novel_mushroom-derived_CDC20_inhibitors_with_antimetastatic_activity
[13]	Zhang MY, Liu XX, Li H, et al. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis[J]. Int J Med Sci, 2018, 15(14): 1676-1685. doi: 10.7150/ijms.28728
[14]	Yi J, Wei X, Li X, et al. A Genome-Wide Comprehensive Analysis of Alterations in Driver Genes in Non-Small-Cell Lung Cancer[J]. Anticancer Drugs, 2018, 29(1): 10-18. doi: 10.1097/CAD.0000000000000571
[15]	Zhang Y, Wang H, Wang J, et al. Global Analysis of Chromosome 1 Genes Among Patients With Lung Adenocarcinoma, Squamous Carcinoma, Large-Cell Carcinoma, Small-Cell Carcinoma, or Non-Cancer[J]. Cancer Metastasis Rev, 2015, 34(2): 249-264. doi: 10.1007/s10555-015-9558-0
[16]	Jan Budczies, Carsten Denkert, Balázs Győrffy, et al. Chromosome 9p Copy Number Gains Involving PD-L1 Are Associated With a Specific Proliferation and Immune-Modulating Gene Expression Program Active Across Major Cancer Types[J]. BMC Med Genomics, 2017, 10(1): 74. doi: 10.1186/s12920-017-0308-8
[17]	Lee A, Moon BI, Kim TH. BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies[J]. Ann Lab Med, 2020, 40(2): 114-121. doi: 10.3343/alm.2020.40.2.114
[18]	Wang B, Cao C, Liu X, et al. BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway[J].Cell Oncol (Dordr), 2020, 43(2): 223-235. doi: 10.1007/s13402-019-00482-8
[19]	Li AG, Murphy EC, Culhane AC, et al. BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation[J]. Proc Natl Acad Sci U S A, 2018, 115(41):E9600-E9609. doi: 10.1073/pnas.1807112115
[20]	Sun X, Cui F, Yin H, et al. Association between EGFR mutation and expression of BRCA1 and RAP80 in non-small cell lung cancer[J].Oncol Lett, 2018, 16(2): 2201-2206.
[21]	Leng XF, Chen MW, Xian L, et al. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy[J]. J Exp Clin Cancer Res, 2012, 31(1): 25. doi: 10.1186/1756-9966-31-25
[22]	Wood K, Hensing T, Malik R, et al. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review[J]. JAMA Oncol, 2016, 2(6): 805-812. doi: 10.1001/jamaoncol.2016.0405

[1]	YANG Tingfang, WANG Li, ZHANG Yong. Expression of FOXO1 in Liver Cancer and Its Prognostic Significance: An Analysis Based on TCGA[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 774-781. DOI: 10.3971/j.issn.1000-8578.2021.21.0221
[2]	JIAO Zhaoshuang, ZHANG Huainian. Establishment and Analysis of MicroRNA Prognostic Risk Model of Papillary Thyroid Carcinoma Based on TCGA Database[J]. Cancer Research on Prevention and Treatment, 2020, 47(4): 262-267. DOI: 10.3971/j.issn.1000-8578.2020.19.0947
[3]	ZHANG Hong, LUO Ruoyu, HU Xiaoxia, CHEN Huan, WANG Linlin. Effect of Overexpression of Follistatin-like Protein 1 on Downstream Genes in Cervical Cancer and Bioinformatic Analysis of Downstream Genes[J]. Cancer Research on Prevention and Treatment, 2019, 46(1): 26-31. DOI: 10.3971/j.issn.1000-8578.2019.18.0665
[4]	TANG Jun, LIU Liming. Expression, Function and Bioinformatic Analysis of Nicotinamide Phosphoribosyl Transferase in Colon Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(12): 991-995. DOI: 10.3971/j.issn.1000-8578.2018.18.0928
[5]	SONG Shangjin, GU You, WANG Yichao, YUE Xiaoqiang. Bioinformatics Analysis of Gastric Intestinal Metaplasia-related Genes and Pathways Based on GEO Database[J]. Cancer Research on Prevention and Treatment, 2018, 45(10): 768-774. DOI: 10.3971/j.issn.1000-8578.2018.17.1651
[6]	CHEN Changxian, HU Yanling, LI Li. Bioinformatics Analysis of Genes Related to Multidrug Resistance in Ovarian Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 492-496. DOI: 10.3971/j.issn.1000-8578.2016.06.012
[7]	ZHANG Lijing, WANG Yuanyuan, ZHAI Congjie, DU Zhijian, HAN Xiaodong, ZHAO Zengren. MicroRNA-31 Expression in Colorectal Cancer and Bioinformatic Analysis of Its Predicted Target Genes[J]. Cancer Research on Prevention and Treatment, 2015, 42(10): 1005-1010. DOI: 10.3971/j.issn.1000-8578.2015.10.012
[8]	LI Jiqiang, HUANG Donglan, SUN Yao, JIANG Maozhu, MAI Zhonglun, ZENG Rong, ZHANG Jiren, ZHENG Yanfang. Bioinformatics Analysis of Susceptibility Genes in Colorectal Cancer from 2001 to 2010[J]. Cancer Research on Prevention and Treatment, 2013, 40(11): 1094-1097. DOI: 10.3971/j.issn.1000-8578.2013.11.017
[9]	JIANG Maozhu, MAI Zhonglun, ZENG Rong, WU Gang, ZHENG Yanfang, ZHANG Jiren. Bioinformatics-based Analysis for microRNAs Expression Profiles between Basal-like and Luminal A Breast Cancers[J]. Cancer Research on Prevention and Treatment, 2013, 40(05): 417-421. DOI: 10.3971/j.issn.1000-8578.2013.05.002
[10]	. Expression and clinical significance of PLCβ4 gene in hepatocellular carcinoma analysed based on TCGA database and experimental validation[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.20241044

Cited By

Cited by

Periodical cited type(2)

1.	莫艳秀，姚飞虹，刘峻彤，胡紫昂，李木兰. SP600125对人宫颈癌HeLa细胞增殖和侵袭的影响. 肿瘤防治研究. 2022(04): 304-313 . 本站查看
2.	赵永，黄萍，郭子文，汪琼. 基于加权基因共表达网络分析慢性阻塞性肺疾病的差异基因及信号通路. 华南国防医学杂志. 2022(12): 959-966 .

Other cited types(2)

Get Citation

PDF

XML

Article views (2630) PDF downloads (735) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Screening and Identification of Key Genes for Clinical Benefit of Immunotherapy on Lung Adenocarcinoma Based on TCGA Database